Cyproterone acetate in the treatment of advanced carcinoma of the prostate

R. B. Smith; P. C. Walsh; W. E. Goodwin

doi:10.1016/S0022-5347(17)60128-9

Cyproterone acetate in the treatment of advanced carcinoma of the prostate

R. B. Smith, P. C. Walsh, W. E. Goodwin

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

28 patients with refractory metastatic carcinoma of the prostate were treated with cyproterone acetate (a synthetic progestin) in doses of 300 mg. daily. In 19 patients followup examinations and evaluations demonstrated beneficial results. It is believed that cyproterone acetate has an important place in the hormonal treatment of prostatic cancer.

Original language	English (US)
Pages (from-to)	106-108
Number of pages	3
Journal	Journal of Urology
Volume	110
Issue number	1
DOIs	https://doi.org/10.1016/S0022-5347(17)60128-9
State	Published - 1973
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/S0022-5347(17)60128-9

Cite this

@article{b93cf66ebace4b499f769983f10e6f77,

title = "Cyproterone acetate in the treatment of advanced carcinoma of the prostate",

abstract = "28 patients with refractory metastatic carcinoma of the prostate were treated with cyproterone acetate (a synthetic progestin) in doses of 300 mg. daily. In 19 patients followup examinations and evaluations demonstrated beneficial results. It is believed that cyproterone acetate has an important place in the hormonal treatment of prostatic cancer.",

author = "Smith, {R. B.} and Walsh, {P. C.} and Goodwin, {W. E.}",

year = "1973",

doi = "10.1016/S0022-5347(17)60128-9",

language = "English (US)",

volume = "110",

pages = "106--108",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Cyproterone acetate in the treatment of advanced carcinoma of the prostate

AU - Smith, R. B.

AU - Walsh, P. C.

AU - Goodwin, W. E.

PY - 1973

Y1 - 1973

N2 - 28 patients with refractory metastatic carcinoma of the prostate were treated with cyproterone acetate (a synthetic progestin) in doses of 300 mg. daily. In 19 patients followup examinations and evaluations demonstrated beneficial results. It is believed that cyproterone acetate has an important place in the hormonal treatment of prostatic cancer.

AB - 28 patients with refractory metastatic carcinoma of the prostate were treated with cyproterone acetate (a synthetic progestin) in doses of 300 mg. daily. In 19 patients followup examinations and evaluations demonstrated beneficial results. It is believed that cyproterone acetate has an important place in the hormonal treatment of prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0015785770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015785770&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(17)60128-9

DO - 10.1016/S0022-5347(17)60128-9

M3 - Article

C2 - 4713345

AN - SCOPUS:0015785770

SN - 0022-5347

VL - 110

SP - 106

EP - 108

JO - Journal of Urology

JF - Journal of Urology

IS - 1

ER -

Cyproterone acetate in the treatment of advanced carcinoma of the prostate

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this